Che

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     MULLEN JAMES C						2. Issuer Name <b>and</b> Ticker or Trading Symbol <b>Editas Medicine, Inc.</b> [ EDIT ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
MULL	<u>EN JAWI</u>	<u>ES C</u>							,		,			X	Direc	tor		10% O	wner
(Last)	(Fi	rst) (I	Middle)			Date of Earliest Transaction (Month/Day/Year)									Office	er (give title v)		Other (below)	specify
C/O EDITAS MEDICINE, INC.,					01/0	01/03/2022								CEO					
11 HURLEY ST.				1															
					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)					1									Line)					
CAMBR	IDGE M	A 0	2141		1									X	Form	filed by On	e Repo	orting Pers	on
,														Form filed by More than One Reporting Person					orting
(City)	(St	ate) (2	Zip)																
		Table	I - N	on-Deriva	tive S	Secui	rities	Ac	quire	d, Dis	sposed of	, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y				Year)	Execution Date		.	3. 4. Securitie Transaction Code (Instr. 8)					nd 5) Securi Benefi		cially d Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
										v	Amount	(A) or (D)	Price	Trans		ction(s) 3 and 4)			(Instr. 4)
Common Stock 01/03/202				22				S <sup>(1)</sup>		18,252 D \$2		\$26.9	548	75,898			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
					its, co	alis, v			T .			_		Ť					1
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on March 4, 2021, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 22, 2021. The sale does not represent a discretionary trade by the Reporting Person.

/s/ James C. Mullen

01/04/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.